BNP Paribas Financial Markets Purchases 57,319 Shares of Quanterix Co. (NASDAQ:QTRX)

BNP Paribas Financial Markets grew its stake in Quanterix Co. (NASDAQ:QTRX - Free Report) by 756.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,896 shares of the company's stock after purchasing an additional 57,319 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.17% of Quanterix worth $690,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Barclays PLC lifted its holdings in shares of Quanterix by 42.3% in the 3rd quarter. Barclays PLC now owns 146,248 shares of the company's stock worth $1,896,000 after acquiring an additional 43,447 shares during the last quarter. Tallon Kerry Patrick purchased a new position in shares of Quanterix during the 4th quarter worth approximately $169,000. Janney Capital Management LLC increased its stake in shares of Quanterix by 40.9% during the 4th quarter. Janney Capital Management LLC now owns 33,192 shares of the company's stock worth $353,000 after purchasing an additional 9,639 shares in the last quarter. abrdn plc grew its stake in Quanterix by 24.4% in the 4th quarter. abrdn plc now owns 206,923 shares of the company's stock worth $2,200,000 after acquiring an additional 40,525 shares during the period. Finally, Valmark Advisers Inc. grew its stake in shares of Quanterix by 88.3% during the 4th quarter. Valmark Advisers Inc. now owns 210,878 shares of the company's stock valued at $2,242,000 after buying an additional 98,883 shares during the period. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on QTRX. Leerink Partnrs lowered shares of Quanterix from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Leerink Partners restated a "market perform" rating and issued a $8.00 target price (down previously from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Canaccord Genuity Group cut their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen lowered shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Scotiabank restated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Quanterix currently has a consensus rating of "Hold" and a consensus target price of $15.60.

Quanterix Stock Up 4.5%

NASDAQ:QTRX traded up $0.23 during trading hours on Wednesday, reaching $5.32. 147,120 shares of the company's stock were exchanged, compared to its average volume of 784,886. The business's 50-day simple moving average is $5.55 and its two-hundred day simple moving average is $8.34. Quanterix Co. has a 12 month low of $4.05 and a 12 month high of $19.17. The company has a market capitalization of $206.57 million, a P/E ratio of -5.02 and a beta of 1.12.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.16. The company had revenue of $30.33 million for the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. As a group, sell-side analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.